Smoking Cessation May Reduce Risk of Visual Field Progression in Heavy Smokers.
Journal
Journal of glaucoma
ISSN: 1536-481X
Titre abrégé: J Glaucoma
Pays: United States
ID NLM: 9300903
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
received:
02
06
2022
accepted:
14
07
2022
pubmed:
9
8
2022
medline:
1
10
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
The earlier a person quits smoking the more likely is the optic nerve be spared from damage. To investigate the effect of smoking cessation on visual field (VF) progression in glaucoma. Primary open angle glaucoma patients with a minimum of 3 years follow-up and 5 VFs were included. Linear mixed models were used to investigate the effects of smoking on the rates of 24-2 VF mean deviation loss after adjusting for confounding factors. Cox proportional hazard regression was used to identify whether different levels of smoking intensity were associated with VF progression with respect to different duration of quitting. Five hundred eleven eyes of 354 patients were included over the mean follow-up of 12.4 years. Mean baseline age (95% confidence interval) was 62.3 (61.2, 63.4) years. One hundred forty nine (42.1%) patients were smokers. In a multivariable model, smoking intensity was associated with faster VF loss (-0.06, 95% confidence interval (-0.10, -0.01) dB/year per 10 pack-years, P =0.01) among smokers. Heavy smokers (≥20 pack-years) who had quit ˂25 years prior had significantly greater odds of VF progression compared with never smokers (odds ratio=2.49 (1.01, 6.08); P =0.046). There was no significant difference in odds of VF progression in heavy smokers who had quit smoking more than 25 years compared with never smokers ( P =0.43). A significantly higher proportion of VF progression was found in heavy smokers who quit < 25 years compared with heavy smokers who quit ≥25 years by Kaplan-Meier analysis ( P =<0.001). After ≥25 years of smoking cessation, the risk of VF progression in former heavy smokers becomes similar to never smokers. Long-term smoking cessation may be associated with lower VF progression in glaucoma patients.
Identifiants
pubmed: 35939832
doi: 10.1097/IJG.0000000000002092
pii: 00061198-202210000-00004
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
796-803Subventions
Organisme : NEI NIH HHS
ID : R01 EY011008
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY023704
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY026574
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029058
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: R.N.W. has received financial support from C: Aerie Pharmaceuticals, Allergan, Equinox, Eyenovia, Nicox, Topcon; F: Heidelberg Engineering, Carl Zeiss Meditec, Konan Medical, Optovue, Centervue, Bausch&Lomb, Topcon; P: Toromedes, Carl Zeiss Meditec, Topcon. C.A.G. has received financial support from National Eye Institute, EyeSight Foundation of Alabama, Research to Prevent Blindness, Heidelberg Engineering, GmbH. J.M.L. has received financial support from C: Alcon, Allergan, Bausch & Lomb, Carl Zeiss Meditec, Heidelberg Engineering, Reichert, Valeant Pharmaceuticals; F: Bausch & Lomb, Carl Zeiss Meditec, Heidelberg Engineering, National Eye Institute, Novartis, Optovue, Reichert Technologies, Research to Prevent Blindness. The remaining authors declare no conflict of interest.
Références
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901–1911.
Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53(suppl 1):S3–S10.
Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965–1972.
Coleman AL, Kodjebacheva G. Risk factors for glaucoma needing more attention. Open Ophthalmol J. 2009;3:38–42.
Perez CI, Singh K, Lin S. Relationship of lifestyle, exercise, and nutrition with glaucoma. Curr Opin Ophthalmol. 2019;30:82–88.
Founti P, Bunce C, Khawaja AP, et al. Risk factors for visual field deterioration in the united kingdom glaucoma treatment study. Ophthalmology. 2020;127:1642–1651.
Bonovas S, Filioussi K, Tsantes A, et al. Epidemiological association between cigarette smoking and primary open-angle glaucoma: a meta-analysis. Public Health. 2004;118:256–261.
Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43:1731–1737.
Akarsu C, Yazici B, Taner P, et al. Effects of moderate smoking on the central visual field. Acta Ophthalmol Scand. 2004;82:432–435.
Congdon NG. Prevention strategies for age related cataract: present limitations and future possibilities. Br J Ophthalmol. 2001;85:516–520.
Age-Related Eye Disease Study Research G. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000;107:2224–2232.
McCarty CA, Mukesh BN, Fu CL, et al. Risk factors for age-related maculopathy: the Visual Impairment Project. Arch Ophthalmol. 2001;119:1455–1462.
Zanon-Moreno V, Garcia-Medina JJ, Zanon-Viguer V, et al. Smoking, an additional risk factor in elder women with primary open-angle glaucoma. Mol Vis. 2009;15:2953–2959.
Edwards R, Thornton J, Ajit R, et al. Cigarette smoking and primary open angle glaucoma: a systematic review. J Glaucoma. 2008;17:558–566.
Doshi V, Ying-Lai M, Azen SP, et al. Sociodemographic, family history, and lifestyle risk factors for open-angle glaucoma and ocular hypertension. The Los Angeles Latino Eye Study. Ophthalmology. 2008;115:639–647;e632.
Topouzis F, Wilson MR, Harris A, et al. Risk factors for primary open-angle glaucoma and pseudoexfoliative glaucoma in the Thessaloniki eye study. Am J Ophthalmol. 2011;152:219–228; e211.
Klein BE, Klein R, Ritter LL. Relationship of drinking alcohol and smoking to prevalence of open-angle glaucoma: the Beaver Dam Eye Study. Ophthalmology. 1993;100:1609–1613.
Wise LA, Rosenberg L, Radin RG, et al. A prospective study of diabetes, lifestyle factors, and glaucoma among African-American women. Ann Epidemiol. 2011;21:430–439.
Ramdas WD, Wolfs RC, Hofman A, et al. Lifestyle and risk of developing open-angle glaucoma: the Rotterdam study. Arch Ophthalmol. 2011;129:767–772.
Zhang X, Kahende J, Fan AZ, et al. Smoking and visual impairment among older adults with age-related eye diseases. Prev Chronic Dis. 2011;8:A84.
Pérez-de-Arcelus M, Toledo E, Martínez-González M, et al. Smoking and incidence of glaucoma: The SUN Cohort. Medicine (Baltimore). 2017;96:e5761.
Renard J-P, Rouland J-F, Bron A, et al. Nutritional, lifestyle and environmental factors in ocular hypertension and primary open-angle glaucoma: an exploratory case–control study. Acta Ophthalmol. 2013;91:505–513.
Jain V, Jain M, Abdull MM, Bastawrous A. The association between cigarette smoking and primary open-angle glaucoma: a systematic review. Int Ophthalmol. 2017;37:291–301.
Mahmoudinezhad G, Nishida T, Weinreb RN, et al. Impact of smoking on visual field progression in a long-term clinical follow-up. Ophthalmology. 2022:S0161-6420(22)00476-6.
Kaiser HJ, Schoetzau A, Flammer J. Blood flow velocity in the extraocular vessels in chronic smokers. Br J Ophthalmol. 1997;81:133–135.
Chávez J, Cano C, Souki A, et al. Effect of cigarette smoking on the oxidant/antioxidant balance in healthy subjects. Am J Ther. 2007;14:189–193.
Rao HL, Pradhan ZS, Suh MH, et al. Optical coherence tomography angiography in glaucoma. J Glaucoma. 2020;29:312–321.
Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. Surv Ophthalmol. 1998;42:535–547.
Mehra K, Roy P, Khare B. Tobacco smoking and glaucoma. Ann Ophthalmol. 1976;8:462–464.
Kim EH, Lee H, Shin DW, et al. Association between weight changes after smoking cessation and cardiovascular disease among the Korean population. Korean J Fam Med. 2017;38:122–129.
Lee D, Lee YR, Oh IH. Cost-effectiveness of smoking cessation programs for hospitalized patients: a systematic review. Eur J Health Econ. 2019;20:1409–1424.
Yanagi M, Misumi M, Kawasaki R, et al. Is the association between smoking and the retinal venular diameter reversible following smoking cessation? Invest Ophthalmol Vis Sci. 2014;55:405–411.
Vingerling JR, Hofman A, Grobbee DE, et al. Age-related macular degeneration and smoking: the rotterdam study. Arch Ophthalmol. 1996;114:1193–1196.
Jamal A, Phillips E, Gentzke AS, et al. Current cigarette smoking among adults—United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67:53.
Parrott S, Godfrey C. Economics of smoking cessation. BMJ. 2004;328:947–949.
Sample PA, Girkin CA, Zangwill LM, et al. The African Descent and Glaucoma Evaluation Study (ADAGES): design and baseline data. Arch Ophthalmol. 2009;127:1136–1145.
Girkin CA, Sample PA, Liebmann JM, et al. African Descent and Glaucoma Evaluation Study (ADAGES): II. Ancestry differences in optic disc, retinal nerve fiber layer, and macular structure in healthy subjects. Arch Ophthalmol. 2010;128:541–550.
Yousefi S, Mahmoudi Nezhad GS, Pourahmad S, et al. Distribution and rates of visual field loss across different disease stages in primary open-angle glaucoma. Ophthalmol Glaucoma. 2018;1:52–60.
Medeiros FA, Zangwill LM, Bowd C, et al. The structure and function relationship in glaucoma: implications for detection of progression and measurement of rates of change. Invest Ophthalmol Vis Sci. 2012;53:6939–6946.
Tindle HA, Stevenson Duncan M, Greevy RA, et al. Lifetime smoking history and risk of lung cancer: results from the Framingham Heart Study. J Natl Cancer Inst. 2018;110:1201–1207.
Duncan MS, Freiberg MS, Greevy RA Jr, et al. Association of smoking cessation with subsequent risk of cardiovascular disease. JAMA. 2019;322:642–650.
Medeiros FA, Zangwill LM, Alencar LM, et al. Rates of progressive retinal nerve fiber layer loss in glaucoma measured by scanning laser polarimetry. Am J Ophthalmol. 2010;149:908–915.
Swaminathan SS, Jammal AA, Berchuck SI, et al. Rapid initial OCT RNFL thinning is predictive of faster visual field loss during extended follow-up in glaucoma. Am J Ophthalmol. 2021;229:100–107.
Chiotoroiu S, de Popa DP, Ştefăniu G, et al. The importance of alcohol abuse and smoking in the evolution of glaucoma disease. J Med Life. 2013;6:226–229.
Rabiolo A, Morales E, Mohamed L, et al. Comparison of methods to detect and measure glaucomatous visual field progression. Transl Vis Sci Technol. 2019;8:2.
Harrell FE. Cox Proportional Hazards Regression Model. Regression Modeling Strategies . New York, NY: Springer; 2015:475-519.
Harrell FE. Regression Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression and Survival Analysis. New York, NY: Springer; 2015.
Chakravarthy U, Augood C, Bentham GC, et al. Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology. 2007;114:1157–1163.
De Bernardo M, Cornetta P, Marotta G, et al. A prospective longitudinal study to investigate corneal hysteresis as a risk factor for predicting development of glaucoma. Am J Ophthalmol. 2018;195:243.
De Moraes CG, Sehi M, Greenfield DS, et al. A validated risk calculator to assess risk and rate of visual field progression in treated glaucoma patients. Invest Ophthalmol Vis Sci. 2012;53:2702–2707.
Gordon MO, Torri V, Miglior S, et al. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology. 2007;114:10–19.
Stagg BC, Stein JD, Medeiros FA, et al. Special commentary: using clinical decision support systems to bring predictive models to the glaucoma clinic. Ophthalmol Glaucoma. 2021;4:5–9.
Schweitzer JA, Ervin M, Berdahl JP. Assessment of corneal hysteresis measured by the ocular response analyzer as a screening tool in patients with glaucoma. Clin Ophthalmol. 2018;12:1809–1813.
Bailey SR, Heintzman JD, Marino M, et al. Smoking-cessation assistance: before and after stage 1 meaningful use implementation. Am J Prev Med. 2017;53:192–200.
Huo J, Yang M, Tina Shih YC. Sensitivity of claims-based algorithms to ascertain smoking status more than doubled with meaningful use. Value Health. 2018;21:334–340.
Kruse GR, Chang Y, Kelley JH, et al. Healthcare system effects of pay-for-performance for smoking status documentation. Am J Manag Care. 2013;19:554–561.
Delcourt C, Diaz J-L, Ponton-Sanchez A, Papoz L, et al. Smoking and Age-related Macular Degeneration: The POLA Study. Arch Ophthalmol. 1998;116:1031–1035.
Research To Prevent Blindness. New Poll Places Fear of Vision Loss at the Top of Americans’ Health Concerns. https://www.rpbusa.org/rpb/news-and-publications/news/latest/page-66/ . Accessed September 29, 2014.
Kim JH, Rabiolo A, Morales E, et al. Risk factors for fast visual field progression in glaucoma. Am J Ophthalmol. 2019;207:268–278.
Spry PG, Sparrow JM, Diamond JP, et al. Risk factors for progressive visual field loss in primary open angle glaucoma. Eye (Lond). 2005;19:643–651.
Kang JH, Pasquale LR, Rosner BA, et al. Prospective study of cigarette smoking and the risk of primary open-angle glaucoma. Arch Ophthalmol. 2003;121:1762–1768.
Kang JH, Wiggs JL, Rosner BA, et al. Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with hypertension, alcohol intake, and cigarette smoking. Arch Ophthalmol. 2011;129:773–780.
Law SM, Lu X, Yu F, et al. Cigarette smoking and glaucoma in the United States population. Eye. 2018;32:716–725.
Tamaki Y, Araie M, Nagahara M, et al. Acute effects of cigarette smoking on tissue circulation in human optic nerve head and choroid-retina. Ophthalmology. 1999;106:564–569.
Kumar S, Majumdar S, Mukherjee S, et al. Evaluation of the effects of moderate to severe smoking on retinal nerve fiber layer thickness. J Evid Based Med Healthc. 2019;6:2349–2562.
Demirci S, Gunes A, Demirci S, et al. The effect of cigarette smoking on retinal nerve fiber layer thickness in patients with migraine. Cutan Ocul Toxicol. 2016;35:21–25.
Moschos MM, Nitoda E, Laios K, et al. The impact of chronic tobacco smoking on retinal and choroidal thickness in Greek Population. Oxid Med Cell Longev. 2016;2016:2905789.
Dervisogullari MS, Totan Y, Tenlik A, et al. Effect of smoking on retina nerve fiber layer and ganglion cell-inner plexiform layer complex. Cutan Ocul Toxicol. 2015;34:282–285.
Duman R, Duman R, Sabaner MC, et al. Effect of smoking on the thickness of retinal layers in healthy smokers. Cutan Ocul Toxicol. 2017;36:366–369.
Khawaja AP, Chan MPY, Garway-Heath DF, et al. Associations with retinal nerve fiber layer measures in the EPIC-Norfolk Eye Study. Invest Ophthalmol Vis Sci. 2013;54:5028–5034.
Çakir B, Çelik E, Doğan E, et al. Evaluation of retinal ganglion cell-inner plexiform layer complex in healthy smokers. Int Ophthalmol. 2017;37:953–956.
Ayhan Z, Kaya M, Ozturk T, et al. Evaluation of macular perfusion in healthy smokers by using optical coherence tomography angiography. Ophthalmic Surg Lasers Imaging Retina. 2017;48:617–622.
Kang JH, Loomis SJ, Rosner BA, et al. Comparison of risk factor profiles for primary open-angle glaucoma subtypes defined by pattern of visual field loss: a prospective study. Invest Ophthalmol Vis Sci. 2015;56:2439–2448.
Hepsen IF, Evereklioglu C. Defective visual field tests in chronic heavy smokers. Acta Ophthalmol Scand. 2001;79:53–56.